Aptose Biosciences Inc. (APTOF): debt financing — Aptose amends Hanmi acquisition deal; meeting moved to March 31, 2026 and gets $11.1M loan

Aptose Biosciences Inc.

Special shareholder meeting for Hanmi acquisition postponed from Jan 16 to March 31, 2026 due to SEC comments.
Aptose enters $11.1M second amended facility with Hanmi; advances capped at $2M each, 6% interest, matures May 31, 2026.
Facility funds clinical development of Tuspetinib for AML triplet therapy.
Arrangement agreement restated to update meeting date; board unanimously recommends shareholders vote FOR.
Facility is a related-party transaction exempt from formal valuation/minority approval due to financial hardship.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Aptose Biosciences Inc. amended credit facility of US$11.1 million with Hanmi Pharmaceuticals Co. Ltd. at six percent (6%) per annum.

Instrument: credit facility
Principal: US$11.1 million
Counterparty: Hanmi Pharmaceuticals Co. Ltd.
Rate: six percent (6%) per annum
Event: amendment

Exact text from the filing

Second Amended and Restated Facility Agreement On February 23, 2026, the Company and Hanmi entered into a US$11.1 million second amended and restated facility agreement with Hanmi (the “ Second A&R Facility Agreement ”).

View on SEC.gov

101 debt financings filed in the last 30 days. Browse all debt financings →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-064847

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.